Arbutus Biopharma (ABUS) Competitors $3.64 +0.01 (+0.28%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends ABUS vs. KALV, KMDA, FSTX, BYSI, MGTA, VCEL, CPRX, IOVA, IDYA, and ARWRShould you be buying Arbutus Biopharma stock or one of its competitors? The main competitors of Arbutus Biopharma include KalVista Pharmaceuticals (KALV), Kamada (KMDA), F-star Therapeutics (FSTX), BeyondSpring (BYSI), Magenta Therapeutics (MGTA), Vericel (VCEL), Catalyst Pharmaceuticals (CPRX), Iovance Biotherapeutics (IOVA), IDEAYA Biosciences (IDYA), and Arrowhead Pharmaceuticals (ARWR). These companies are all part of the "medical" sector. Arbutus Biopharma vs. KalVista Pharmaceuticals Kamada F-star Therapeutics BeyondSpring Magenta Therapeutics Vericel Catalyst Pharmaceuticals Iovance Biotherapeutics IDEAYA Biosciences Arrowhead Pharmaceuticals KalVista Pharmaceuticals (NASDAQ:KALV) and Arbutus Biopharma (NASDAQ:ABUS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, community ranking, dividends, analyst recommendations, earnings, media sentiment, institutional ownership and profitability. Does the MarketBeat Community prefer KALV or ABUS? Arbutus Biopharma received 95 more outperform votes than KalVista Pharmaceuticals when rated by MarketBeat users. However, 74.39% of users gave KalVista Pharmaceuticals an outperform vote while only 70.94% of users gave Arbutus Biopharma an outperform vote. CompanyUnderperformOutperformKalVista PharmaceuticalsOutperform Votes33774.39% Underperform Votes11625.61% Arbutus BiopharmaOutperform Votes43270.94% Underperform Votes17729.06% Which has stronger valuation & earnings, KALV or ABUS? Arbutus Biopharma has higher revenue and earnings than KalVista Pharmaceuticals. Arbutus Biopharma is trading at a lower price-to-earnings ratio than KalVista Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKalVista PharmaceuticalsN/AN/A-$126.64M-$3.53-2.69Arbutus Biopharma$18.14M38.02-$72.85M-$0.43-8.46 Does the media refer more to KALV or ABUS? In the previous week, Arbutus Biopharma had 16 more articles in the media than KalVista Pharmaceuticals. MarketBeat recorded 18 mentions for Arbutus Biopharma and 2 mentions for KalVista Pharmaceuticals. KalVista Pharmaceuticals' average media sentiment score of 0.96 beat Arbutus Biopharma's score of 0.20 indicating that KalVista Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment KalVista Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arbutus Biopharma 2 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders and institutionals have more ownership in KALV or ABUS? 43.8% of Arbutus Biopharma shares are held by institutional investors. 10.5% of KalVista Pharmaceuticals shares are held by insiders. Comparatively, 4.0% of Arbutus Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has more volatility & risk, KALV or ABUS? KalVista Pharmaceuticals has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500. Comparatively, Arbutus Biopharma has a beta of 1.92, indicating that its stock price is 92% more volatile than the S&P 500. Do analysts prefer KALV or ABUS? KalVista Pharmaceuticals currently has a consensus price target of $26.00, indicating a potential upside of 173.97%. Arbutus Biopharma has a consensus price target of $5.38, indicating a potential upside of 47.66%. Given KalVista Pharmaceuticals' higher probable upside, equities research analysts clearly believe KalVista Pharmaceuticals is more favorable than Arbutus Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score KalVista Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Arbutus Biopharma 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is KALV or ABUS more profitable? KalVista Pharmaceuticals has a net margin of 0.00% compared to Arbutus Biopharma's net margin of -1,137.65%. Arbutus Biopharma's return on equity of -68.18% beat KalVista Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets KalVista PharmaceuticalsN/A -97.37% -82.39% Arbutus Biopharma -1,137.65%-68.18%-51.55% SummaryArbutus Biopharma beats KalVista Pharmaceuticals on 10 of the 16 factors compared between the two stocks. Ad WealthPressHow one pattern has averaged an 85% return per year since the pandemic. Over the last 5 years Roger Scott has done some pretty incredible things… He’s found hundreds of winning opportunities… He’s created some incredible strategies… And he’s even designed some amazing tools… But there is one thing he’s always kept close to the chest… And in this case, it’s been a very particular stock market pattern…. A pattern he calls the World's Most Predictable Pattern…Follow this link here and enter your email address to sign up… Get Arbutus Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ABUS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ABUS vs. The Competition Export to ExcelMetricArbutus BiopharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$689.74M$6.39B$5.06B$8.67BDividend YieldN/A8.04%5.06%4.06%P/E Ratio-8.4610.0598.5017.08Price / Sales38.02266.581,205.7371.31Price / CashN/A53.4940.6936.36Price / Book6.509.306.325.87Net Income-$72.85M$154.14M$119.47M$225.66M7 Day Performance-2.93%-9.49%-5.11%-1.34%1 Month Performance-13.33%-7.23%-3.21%1.00%1 Year Performance96.76%30.70%32.41%25.27% Arbutus Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ABUSArbutus Biopharma2.8115 of 5 stars$3.64+0.3%$5.38+47.7%+96.8%$689.75M$18.14M-8.4673Short Interest ↓News CoverageHigh Trading VolumeKALVKalVista Pharmaceuticals3.8357 of 5 stars$10.67-3.8%N/A+24.7%$461.16MN/A-3.02150Positive NewsKMDAKamada3.9768 of 5 stars$6.27+2.8%N/A+22.8%$360.40M$154.57M23.22360Analyst ForecastShort Interest ↑Analyst RevisionNews CoverageHigh Trading VolumeFSTXF-star TherapeuticsN/A$7.12flatN/AN/A$156.50M$21.17M-3.9184News CoverageBYSIBeyondSpringN/A$1.86-6.1%N/A+73.4%$72.60M$1.75M0.0080Gap DownMGTAMagenta Therapeutics0.8615 of 5 stars$0.70-7.7%N/A+0.0%$42.44MN/A0.0067News CoverageGap DownVCELVericel0.8589 of 5 stars$55.89-1.6%N/A+47.5%$2.76B$226.84M931.66300CPRXCatalyst Pharmaceuticals4.7199 of 5 stars$23.04-1.7%N/A+54.0%$2.75B$398.20M19.53167IOVAIovance Biotherapeutics4.2756 of 5 stars$9.69-9.0%N/A+85.9%$2.71B$1.19M-6.50500Insider SellingIDYAIDEAYA Biosciences4.191 of 5 stars$30.98-3.1%N/A-11.0%$2.68B$23.39M-13.3080ARWRArrowhead Pharmaceuticals3.7112 of 5 stars$21.51-2.1%N/A-28.7%$2.67B$19.65M-4.61400Analyst UpgradeNews Coverage Related Companies and Tools Related Companies KALV Alternatives KMDA Alternatives FSTX Alternatives BYSI Alternatives MGTA Alternatives VCEL Alternatives CPRX Alternatives IOVA Alternatives IDYA Alternatives ARWR Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ABUS) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arbutus Biopharma Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arbutus Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ABUS Stock Alerts